Skip to main content
Erschienen in: World Journal of Surgery 2/2007

01.02.2007

Pancreatoduodenectomy for Distal Cholangiocarcinoma: Prognostic Impact of Lymph Node Metastasis

verfasst von: Yoshiaki Murakami, MD, Kenichiro Uemura, MD, Yasuo Hayashidani, MD, Takeshi Sudo, MD, Hiroki Ohge, MD, Taijiro Sueda, MD

Erschienen in: World Journal of Surgery | Ausgabe 2/2007

Einloggen, um Zugang zu erhalten

Abstract

Background

The aim of this study was to identify useful prognostic factors in patients undergoing pancreatoduodenectomy for distal cholangiocarcinoma.

Methods

The records of 36 patients with distal cholangiocarcinoma undergoing pancreatoduodenectomy were retrospectively reviewed. Potential clinicopathological prognostic factors that may affect survival were examined by univariate and multivariate analysis.

Results

There was no mortality. Overall survival rates were 75%, 54%, and 50% for 1, 3 and 5 years, respectively (median survival time, 26 months). Univariate analysis found that age (≧ 65 years), pancreatic invasion, duodenal invasion, lymph node metastasis, perineural invasion and a positive surgical margin were significant predictors of poor prognosis (P < 0.05). Furthermore, lymph node metastasis was found to be a significant independent predictor of poor prognosis by multivariate analysis (P = 0.043). Moreover, there were significant differences in the 5-year survival between patients with 2 or less involved lymph nodes and those with 3 or more positive nodes (P < 0.001). There were no 2-year survivors of the group of patients with 3 or more positive nodes.

Conclusions

These results suggest that the presence and number of lymph nodes exhibiting metastatic disease might be useful in predicting the postsurgical outcome in patients undergoing pancreatoduodenectomy for distal cholangiocarcinoma.
Literatur
1.
Zurück zum Zitat Nakeeb A, Pitt HA, Sohn TA, et al. Cholangiocarcinoma. A spectrum of intrahepatic, perihilar, and distal tumors. Ann Surg 1996;224:463–473PubMedCrossRef Nakeeb A, Pitt HA, Sohn TA, et al. Cholangiocarcinoma. A spectrum of intrahepatic, perihilar, and distal tumors. Ann Surg 1996;224:463–473PubMedCrossRef
2.
Zurück zum Zitat Hejna M, Pruckmayer M, Raderer M. The role of chemotherapy and radiation in the management of biliary cancer: a review of the literature. Eur J Cancer 1998;34:977–986PubMedCrossRef Hejna M, Pruckmayer M, Raderer M. The role of chemotherapy and radiation in the management of biliary cancer: a review of the literature. Eur J Cancer 1998;34:977–986PubMedCrossRef
3.
Zurück zum Zitat Yee K, Sheppard BC, Domreis J, et al. Cancers of the gallbladder and biliary ducts. Oncology (Williston Park) 2002;16:939–957 Yee K, Sheppard BC, Domreis J, et al. Cancers of the gallbladder and biliary ducts. Oncology (Williston Park) 2002;16:939–957
4.
Zurück zum Zitat Park SW, Park YS, Chung JB, et al. Patterns and relevant factors of tumor recurrence for extrahepatic bile duct carcinoma after radical resection. Hepatogastroenterology 2004;51:1612–1618PubMed Park SW, Park YS, Chung JB, et al. Patterns and relevant factors of tumor recurrence for extrahepatic bile duct carcinoma after radical resection. Hepatogastroenterology 2004;51:1612–1618PubMed
5.
Zurück zum Zitat Yoshida T, Matsumoto T, Sasaki A, et al. Prognostic factors after pancreatoduodenectomy with extended lymphadenectomy for distal bile duct cancer. Arch Surg 2002;137:69–73PubMedCrossRef Yoshida T, Matsumoto T, Sasaki A, et al. Prognostic factors after pancreatoduodenectomy with extended lymphadenectomy for distal bile duct cancer. Arch Surg 2002;137:69–73PubMedCrossRef
6.
Zurück zum Zitat Sasaki R, Takahashi M, Funato O, et al. Prognostic significance of lymph node involvement in middle and distal bile duct cancer. Surgery 2001;129:677–683PubMedCrossRef Sasaki R, Takahashi M, Funato O, et al. Prognostic significance of lymph node involvement in middle and distal bile duct cancer. Surgery 2001;129:677–683PubMedCrossRef
7.
Zurück zum Zitat Suzuki M, Unno M, Oikawa M, et al. Surgical treatment and postoperative outcomes for middle and lower bile duct carcinoma in Japan: experience of a single institute. Hepatogastroenterology 2000;47:650–657PubMed Suzuki M, Unno M, Oikawa M, et al. Surgical treatment and postoperative outcomes for middle and lower bile duct carcinoma in Japan: experience of a single institute. Hepatogastroenterology 2000;47:650–657PubMed
8.
Zurück zum Zitat Kayahara M, Nagakawa T, Ohta T, et al. Role of nodal involvement and the periductal soft-tissue margin in middle and distal bile duct cancer. Ann Surg 1999;229:76–83PubMedCrossRef Kayahara M, Nagakawa T, Ohta T, et al. Role of nodal involvement and the periductal soft-tissue margin in middle and distal bile duct cancer. Ann Surg 1999;229:76–83PubMedCrossRef
9.
Zurück zum Zitat Zerbi A, Balzano G, Leone BE, et al. Clinical presentation, diagnosis and survival of resected distal bile duct cancer. Dig Surg 1998;15:410–416PubMedCrossRef Zerbi A, Balzano G, Leone BE, et al. Clinical presentation, diagnosis and survival of resected distal bile duct cancer. Dig Surg 1998;15:410–416PubMedCrossRef
10.
Zurück zum Zitat Wade TP, Prasad CN, Virgo KS, et al. Experience with distal bile duct cancers in U.S. Veterans Affairs hospitals: 1987–1991. J Surg Oncol 1997;64:242–245PubMedCrossRef Wade TP, Prasad CN, Virgo KS, et al. Experience with distal bile duct cancers in U.S. Veterans Affairs hospitals: 1987–1991. J Surg Oncol 1997;64:242–245PubMedCrossRef
11.
Zurück zum Zitat Fong Y, Blumgart LH, Lin E, et al. Outcome of treatment for distal bile duct cancer. Br J Surg 1996;83:1712–1715PubMed Fong Y, Blumgart LH, Lin E, et al. Outcome of treatment for distal bile duct cancer. Br J Surg 1996;83:1712–1715PubMed
12.
Zurück zum Zitat Nagorney DM, Donohue JH, Farnell MB, et al. Outcomes after curative resections of cholangiocarcinoma. Arch Surg 1993;128:871–877PubMed Nagorney DM, Donohue JH, Farnell MB, et al. Outcomes after curative resections of cholangiocarcinoma. Arch Surg 1993;128:871–877PubMed
13.
Zurück zum Zitat Sakamoto Y, Kosuge T, Shimada K, et al. Prognostic factors of surgical resection in middle and distal bile duct cancer: an analysis of 55 patients concerning the significance of ductal and radial margins. Surgery 2005;137:396–402PubMedCrossRef Sakamoto Y, Kosuge T, Shimada K, et al. Prognostic factors of surgical resection in middle and distal bile duct cancer: an analysis of 55 patients concerning the significance of ductal and radial margins. Surgery 2005;137:396–402PubMedCrossRef
14.
Zurück zum Zitat Reding R, Buard JL, Lebeau G, et al. Surgical management of 552 carcinomas of the extrahepatic bile ducts (gallbladder and periampullary tumors excluded). Results of the French Surgical Association Survey. Ann Surg 1991;213:236–241PubMedCrossRef Reding R, Buard JL, Lebeau G, et al. Surgical management of 552 carcinomas of the extrahepatic bile ducts (gallbladder and periampullary tumors excluded). Results of the French Surgical Association Survey. Ann Surg 1991;213:236–241PubMedCrossRef
15.
Zurück zum Zitat Washburn WK, Lewis WD, Jenkins RL. Aggressive surgical resection for cholangiocarcinoma. Arch Surg 1995;130:270–276PubMed Washburn WK, Lewis WD, Jenkins RL. Aggressive surgical resection for cholangiocarcinoma. Arch Surg 1995;130:270–276PubMed
16.
Zurück zum Zitat Schoenthaler R, Phillips TL, Castro J, et al. Carcinoma of the extrahepatic bile ducts. The University of California at San Francisco experience. Ann Surg 1994;219:267–274PubMedCrossRef Schoenthaler R, Phillips TL, Castro J, et al. Carcinoma of the extrahepatic bile ducts. The University of California at San Francisco experience. Ann Surg 1994;219:267–274PubMedCrossRef
17.
Zurück zum Zitat Guthrie CM, Haddock G, De Beaux AC, et al. Changing trends in the management of extrahepatic cholangiocarcinoma. Br J Surg 1993;80:1434–1439PubMed Guthrie CM, Haddock G, De Beaux AC, et al. Changing trends in the management of extrahepatic cholangiocarcinoma. Br J Surg 1993;80:1434–1439PubMed
18.
Zurück zum Zitat Japanese Society of Biliary Surgery. General rules for surgical and pathological studies on cancer of biliary tract, 4th edition. Tokyo, Kanehara, 1997 Japanese Society of Biliary Surgery. General rules for surgical and pathological studies on cancer of biliary tract, 4th edition. Tokyo, Kanehara, 1997
19.
Zurück zum Zitat Inoue K, Makuuchi M, Takayama T, et al. Long-term survival and prognostic factors in the surgical treatment of mass-forming type cholangiocarcinoma. Surgery 2000;127:498–505PubMed Inoue K, Makuuchi M, Takayama T, et al. Long-term survival and prognostic factors in the surgical treatment of mass-forming type cholangiocarcinoma. Surgery 2000;127:498–505PubMed
20.
Zurück zum Zitat Ebata T, Nagino M, Kamiya J, et al. Hepatectomy with portal vein resection for hilar cholangiocarcinoma: audit of 52 consecutive cases. Ann Surg 2003;238:720–727PubMedCrossRef Ebata T, Nagino M, Kamiya J, et al. Hepatectomy with portal vein resection for hilar cholangiocarcinoma: audit of 52 consecutive cases. Ann Surg 2003;238:720–727PubMedCrossRef
21.
Zurück zum Zitat de Aretxabala X, Roa I, Burgos L, et al. Gallbladder cancer: an analysis of a series of 139 patients with invasion restricted to the subserosal layer. J Gastrointest Surg 2006;10:186–192PubMedCrossRef de Aretxabala X, Roa I, Burgos L, et al. Gallbladder cancer: an analysis of a series of 139 patients with invasion restricted to the subserosal layer. J Gastrointest Surg 2006;10:186–192PubMedCrossRef
22.
Zurück zum Zitat Sobin LH, Wittekind C, editors. Internatinal Union Against Cancer (UICC): TNM Classification of Malignant Tumors, 6th edition. New York: Wiley-Liss, 2002 Sobin LH, Wittekind C, editors. Internatinal Union Against Cancer (UICC): TNM Classification of Malignant Tumors, 6th edition. New York: Wiley-Liss, 2002
23.
Zurück zum Zitat Nakagawa T, Kamiyama T, Kurauchi N, et al. Number of lymph node metastases is a significant prognostic factor in intrahepatic cholangiocarcinoma. World J Surg 2005;29:728–733PubMedCrossRef Nakagawa T, Kamiyama T, Kurauchi N, et al. Number of lymph node metastases is a significant prognostic factor in intrahepatic cholangiocarcinoma. World J Surg 2005;29:728–733PubMedCrossRef
24.
Zurück zum Zitat Hong SM, Cho H, Lee OJ, et al. The number of metastatic lymph nodes in extrahepatic bile duct carcinoma as a prognostic factor. Am J Surg Pathol 2005;29:1177–1183PubMedCrossRef Hong SM, Cho H, Lee OJ, et al. The number of metastatic lymph nodes in extrahepatic bile duct carcinoma as a prognostic factor. Am J Surg Pathol 2005;29:1177–1183PubMedCrossRef
25.
Zurück zum Zitat Roder JD, Schneider PM, Stein HJ, et al. Number of lymph node metastases is significantly associated with survival in patients with radically resected carcinoma of the ampulla of Vater. Br J Surg 1995;82:1693–1696PubMed Roder JD, Schneider PM, Stein HJ, et al. Number of lymph node metastases is significantly associated with survival in patients with radically resected carcinoma of the ampulla of Vater. Br J Surg 1995;82:1693–1696PubMed
26.
Zurück zum Zitat Alberts SR, Al-Khatib H, Mahoney MR, et al. Gemcitabine, 5-fluorouracil, and leucovorin in advanced biliary tract and gallbladder carcinoma: a North Central Cancer Treatment Group phase II trial. Cancer 2005;103:111–118PubMedCrossRef Alberts SR, Al-Khatib H, Mahoney MR, et al. Gemcitabine, 5-fluorouracil, and leucovorin in advanced biliary tract and gallbladder carcinoma: a North Central Cancer Treatment Group phase II trial. Cancer 2005;103:111–118PubMedCrossRef
27.
Zurück zum Zitat Penz M, Kornek GV, Raderer M, et al. Phase II trial of two-weekly gemcitabine in patients with advanced biliary tract cancer. Ann Oncol 2001;12:183–186PubMedCrossRef Penz M, Kornek GV, Raderer M, et al. Phase II trial of two-weekly gemcitabine in patients with advanced biliary tract cancer. Ann Oncol 2001;12:183–186PubMedCrossRef
Metadaten
Titel
Pancreatoduodenectomy for Distal Cholangiocarcinoma: Prognostic Impact of Lymph Node Metastasis
verfasst von
Yoshiaki Murakami, MD
Kenichiro Uemura, MD
Yasuo Hayashidani, MD
Takeshi Sudo, MD
Hiroki Ohge, MD
Taijiro Sueda, MD
Publikationsdatum
01.02.2007
Erschienen in
World Journal of Surgery / Ausgabe 2/2007
Print ISSN: 0364-2313
Elektronische ISSN: 1432-2323
DOI
https://doi.org/10.1007/s00268-006-0224-0

Weitere Artikel der Ausgabe 2/2007

World Journal of Surgery 2/2007 Zur Ausgabe

Update Chirurgie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

S3-Leitlinie „Diagnostik und Therapie des Karpaltunnelsyndroms“

Karpaltunnelsyndrom BDC Leitlinien Webinare
CME: 2 Punkte

Das Karpaltunnelsyndrom ist die häufigste Kompressionsneuropathie peripherer Nerven. Obwohl die Anamnese mit dem nächtlichen Einschlafen der Hand (Brachialgia parästhetica nocturna) sehr typisch ist, ist eine klinisch-neurologische Untersuchung und Elektroneurografie in manchen Fällen auch eine Neurosonografie erforderlich. Im Anfangsstadium sind konservative Maßnahmen (Handgelenksschiene, Ergotherapie) empfehlenswert. Bei nicht Ansprechen der konservativen Therapie oder Auftreten von neurologischen Ausfällen ist eine Dekompression des N. medianus am Karpaltunnel indiziert.

Prof. Dr. med. Gregor Antoniadis
Berufsverband der Deutschen Chirurgie e.V.

S2e-Leitlinie „Distale Radiusfraktur“

Radiusfraktur BDC Leitlinien Webinare
CME: 2 Punkte

Das Webinar beschäftigt sich mit Fragen und Antworten zu Diagnostik und Klassifikation sowie Möglichkeiten des Ausschlusses von Zusatzverletzungen. Die Referenten erläutern, welche Frakturen konservativ behandelt werden können und wie. Das Webinar beantwortet die Frage nach aktuellen operativen Therapiekonzepten: Welcher Zugang, welches Osteosynthesematerial? Auf was muss bei der Nachbehandlung der distalen Radiusfraktur geachtet werden?

PD Dr. med. Oliver Pieske
Dr. med. Benjamin Meyknecht
Berufsverband der Deutschen Chirurgie e.V.

S1-Leitlinie „Empfehlungen zur Therapie der akuten Appendizitis bei Erwachsenen“

Appendizitis BDC Leitlinien Webinare
CME: 2 Punkte

Inhalte des Webinars zur S1-Leitlinie „Empfehlungen zur Therapie der akuten Appendizitis bei Erwachsenen“ sind die Darstellung des Projektes und des Erstellungswegs zur S1-Leitlinie, die Erläuterung der klinischen Relevanz der Klassifikation EAES 2015, die wissenschaftliche Begründung der wichtigsten Empfehlungen und die Darstellung stadiengerechter Therapieoptionen.

Dr. med. Mihailo Andric
Berufsverband der Deutschen Chirurgie e.V.